Disruption and development: the evolving CRISPR patent and technology landscape.

Abstract

Pharmaceutical Patent AnalystVol. 7, No. 4 CommentaryDisruption and development: the evolving CRISPR patent and technology landscapeDaniel LimDaniel Lim*Author for correspondence: Tel.: +44 20 3088 3769; E-mail Address: Daniel.lim@allenovery.com Allen & Overy LLP, One Bishops Square, London E1 6AD, UKSearch for more papers by this authorPublished Online:8 Jun 2018https://doi.org/10.4155/ppa-2018-0010AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: Broad InstituteCas9CRISPREPOEuropegene editinggene therapylicensingpatentspriorityrevocationReferences1 The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College: EP2771468 (2015).Google Scholar2 Gaudelli NM, Komor AC, Rees HA et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).Crossref, Medline, CAS, Google Scholar3 Hu JH, Miller SM, Geurts MH et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556, 57–63 (2018).Crossref, Medline, CAS, Google Scholar4 Gootenberg JS, Abudayyeh OO, Kellner MJ et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science doi:10.1126/science.aaq0179 (2018) (Epub ahead of print).Crossref, Google Scholar5 Statement and Background on the CRISPR Patent Process (2018). www.broadinstitute.org/crispr/journalists-statement-and-background-crispr-patent-process.Google Scholar6 The Regents of the University of California, University of Vienna, Emmanuelle Charpentier: EP2800811 (2017).Google Scholar7 The Regents of the University of California, University of Vienna, Emmanuelle Charpentier: EP3241902 (2018).Google Scholar8 Liu XS, Wu H, Krzisch M et al. Rescue of fragile X syndrome neurons by DNA Methylation editing of the FMR1 gene. Cell 172(5), 979–992 (2018).Crossref, Medline, CAS, Google Scholar9 Chen JS, Ma E, Harrington LB et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science doi:10.1126/science.aar6245 (2018) (Epub ahead of print).Google Scholar10 Jinek M, Chylinski K, Fonfara I et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096), 816–821 (2012).Crossref, Medline, CAS, Google Scholar11 The CRISPR Journal. https://home.liebertpub.com/publications/the-crispr-journal/642.Google Scholar12 Barrangou R, Fremaux C, Deveau H et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819), 1709–1712 (2007).Crossref, Medline, CAS, Google Scholar13 Sherkow JS. The CRISPR patent landscape: past, present and future. CRISPR J. 1(1), 5–9 (2018).Crossref, Medline, Google Scholar14 Gene-edited CRISPR mushroom escapes US regulation (2016). www.nature.com/news/gene-edited-crispr-mushroom-escapes-us-regulation-1.19754.Crossref, Google Scholar15 DowDuPont revealed as the surprise leader in global CRISPR patents; study points to potential trouble ahead (2018). www.iam-media.com/blog/detail.aspx?g=4efeae13–7f84–4a30-b414–88a4e6d917ec.Google Scholar16 DuPont Pioneer expands CRISPR-Cas9 patent portfolio with license from Broad Institute of MIT and Harvard (2017). www.pioneer.com/home/site/about/news-media/news-releases/template.CONTENT/guid.EA02CAA5–07DA-AA4D-D17A-E2C6AE20D9FF.Google Scholar17 Sangamo Therapeutics, Inc.: US9873894 (2018); Sangamo Therapeutics, Inc.: US9902974 (2018).Google Scholar18 DuPont Pioneer and Broad Institute join forces to enable democratic CRISPR licensing in agriculture (2017). www.broadinstitute.org/news/dupont-pioneer-and-broad-institute-join-forces-enable-democratic-crispr-licensing-agriculture.Google Scholar19 Broad Institute of MIT and Harvard joins discussions to create worldwide CRISPR-Cas9 licensing pool (2017). www.broadinstitute.org/news/broad-institute-mit-and-harvard-joins-discussions-create-worldwide-crispr-cas9-licensing-pool.Google Scholar20 Benson Hill Biosystems receives patent for novel CRISPR technology (2018). https://bensonhillbio.com/benson-hill-biosystems-receives-patent-novel-crispr-technology/.Google Scholar21 Inscripta releases new, unique CRISPR gene-editing enzyme; free to use for all researchers (2017). www.inscripta.com/news/2017/12/13/inscripta-releases-new-unique-crispr-gene-editing-enzyme-free-to-use-for-all-researchers/.Google Scholar22 Editas Medicine extends CRISPR genome editing leadership through licensing of new CRISPR technologies (2016). http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-newsArticle&ID=2230504.Crossref, Google Scholar23 Monsanto Announces global genome-editing licensing agreement with Broad Institute for newly-characterized CRISPR system (2017). https://monsanto.com/news-releases/monsanto-announces-global-genome-editing-licensing-agreement-with-broad-institute-for-newly-characterized-crispr-system/.Google Scholar24 MADzymes terms & conditions (2018). www.inscripta.com/madzymes/terms/.Google Scholar25 Gene-editing startup Inscripta raises $55.5million (2018). www.reuters.com/article/us-inscripta-fundraising/gene-editing-startup-inscripta-raises-55–5-million-idUSKCN1GC1GP.Google ScholarFiguresReferencesRelatedDetailsCited ByApplication of CRISPR‐Cas9 Technology in Bovine Reproduction3 May 2021CRISPeering: Bioengineering the Host Cells through CRISPRCas9 Genome Editing System as the Next-generation of Cell FactoriesRecent Patents on Biotechnology, Vol. 15, No. 2The trends in CRISPR research: A patent and literature study with a focus on IndiaWorld Patent Information, Vol. 65Patents and the experimental space: social, legal and geographical dimensions of 3D bioprinting25 June 2020 | International Review of Law, Computers & Technology, Vol. 35, No. 1Worldwide CRISPR patent landscape shows strong geographical biases4 June 2019 | Nature Biotechnology, Vol. 37, No. 6 Vol. 7, No. 4 Follow us on social media for the latest updates Metrics Downloaded 211 times History Received 6 April 2018 Accepted 13 April 2018 Published online 8 June 2018 Published in print July 2018 Information© 2018 Newlands PressKeywordsBroad InstituteCas9CRISPREPOEuropegene editinggene therapylicensingpatentspriorityrevocationFinancial & competing interests disclosureThe author is an employee of Allen & Overy LLP. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download